Annual Reports

 
Other

  • 6-K (Mar 12, 2018)
  • 6-K (Mar 7, 2018)
  • IRANNOTICE (Mar 6, 2018)
  • 6-K (Mar 1, 2018)
  • 6-K (Feb 23, 2018)
  • 6-K (Feb 20, 2018)
AstraZeneca 6-K 2015

Documents found in this filing:

  1. 6-K
  2. 6-K
azn201512026k.htm



FORM 6-K


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Report of Foreign Issuer


Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of  December 2015

Commission File Number:  001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X            Form 40-F  __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):            

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  __                 No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):   82-_____________
 

 


LATE-STAGE PIPELINE CONFERENCE CALL
FOR INVESTORS AND ANALYSTS>
 
 
AstraZeneca PLC ("AstraZeneca", "the Company") will today host a conference call for investors and analysts. This will focus on key potential medicines within the late-stage pipeline and will provide further details on the progress made in 2015 and the anticipated news flow in 2016. No material new information will be included; the call is intended to offer additional insight on the pipeline.
 
The event will be led by Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer, alongside AstraZeneca experts from each of the Company's main therapy areas and will take place at 16:00 - 17:30 GMT (11:00 - 12:30 EST).
 
The dial-in details for the conference call are as follows:
 
UK
0800 694 2370
US
866 977 7645
International
+44 1452 557749
Sweden
0200 883 079
Code
79258160
 
The accompanying presentation will be available for download at astrazeneca.com/investors one hour prior to the start of the call. A link to the live audio webcast will also be available at this address. An indexed version and transcript of the webcast will be published in due course.
 
A replay of the call can be accessed from 17:30 GMT today via the following numbers:
 
 
UK
0800 953 1533
US
866 247 4222
International
+44 1452 550000
Code
79258160
 
Reporting Calendar>
The Company intends to publish its full-year financial results on 4 February 2016.
 
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit: www.astrazeneca.com
 
 
CONTACTS>
 
 
Media Enquiries
 
   
Esra Erkal-Paler
 
UK/Global
+44 20 7604 8030
Vanessa Rhodes
 
UK/Global
+44 20 7604 8037
Karen Birmingham
UK/Global
+44 20 7604 8120
Jacob Lund
 
Sweden
+46 8 553 260 20
Michele Meixell
US
+1 302 885 2677
 
Investor Enquiries
   
    UK
          
    Thomas Kudsk Larsen
Oncology
+44 7818 524185
   
    Eugenia Litz
RIA
+44 7884 735627
   
    Nick Stone
CVMD
+44 7717 618834
   
    Craig Marks
Finance
+44 7881 615764
   
    Christer Gruvris
Consensus Forecasts
+44 7827 836825
   
US
       
    Lindsey Trickett
Oncology, ING
+1 240 543 7970
   
    Mitchell Chan
Oncology
+1 240 477 3771
   
    Toll-Free
 
+1 866 381 7277
   
             
 
Key: RIA - Respiratory, Inflammation & Autoimmunity, CVMD - Cardiovascular & Metabolic Disease, 
   ING - Infection, Neuroscience & Gastrointestinal
 
 
02 December 2015
 
 
-ENDS-
 

 


 
SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC




Date: 02 December 2015
By:  /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki